Obseva SA (NASDAQ: OBSV)
Obseva is likely to have a great day in the market today, and for good reason. The company announced early this morning that it has initiated a key Phase 3 clinical program. Today, we’ll talk about the Phase 3 trial initiation as well as what we’ll be watching for with regard to OBSV ahead.
OBSV Initiates Key Phase 3 Trial
As mentioned above, Obseva is likely to have a strong day in the market today. That’s because the Swiss biopharmaceutical company has announced the initiation of a key Phase 3 clinical program early this morning.
The clinical program is designed around the company’s flagship candidate, nolassiban. The treatment is being studied throughout 10 European countries as a treatment that improves pregnancy and live birth rates in women who are undergoing ART. The Phase 3 study will evaluate both the safety and efficacy of the treatment.
It is expected that the Phase 3 trial will be overwhelmingly positive. That’s because in Phase 2 OBSV proved that 43% of patients treated with 900 mg of nolasiban before ET achieved a live birt compared to 29% of patients that were given a placebo. In a statement, Ernest Loumaye, MD, Phd, OB&GYN, CEO and Co-Founder of OBSV, had the following to offer…
“Based on our promising Phase 2 data, we are starting a large confirmatory study to assess the efficacy and safety of a single, oral administration of 900 mg of nolasiban before embryo transfer on either Day 3 or Day 5 following egg retrieval… We believe that should this trial confirm an absolute increase in live birth rates of about 10 percent, or greater, it would represent a major advance for the patients undergoing these demanding procedures to fulfill their desire to have a child.”
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will be keeping a close eye on OBSV. In particular, we’ll be following the Phase 3 clinical trial of nolasiban and we are excited as we are expecting a positive outcome. Nonetheless, we’ll be watching the news closely and continuing to bring it to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!
[Image Courtesy of Pixabay]